Literature DB >> 20663721

Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.

Aslaug Aamodt Muggerud1, Michael Hallett, Hilde Johnsen, Kristine Kleivi, Wenjing Zhou, Simin Tahmasebpoor, Rose-Marie Amini, Johan Botling, Anne-Lise Børresen-Dale, Therese Sørlie, Fredrik Wärnberg.   

Abstract

Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer where cells restricted to the ducts exhibit an atypical phenotype. Some DCIS lesions are believed to rapidly transit to invasive ductal carcinomas (IDCs), while others remain unchanged. Existing classification systems for DCIS fail to identify those lesions that transit to IDC. We studied gene expression patterns of 31 pure DCIS, 36 pure invasive cancers and 42 cases of mixed diagnosis (invasive cancer with an in situ component) using Agilent Whole Human Genome Oligo Microarrays 44k. Six normal breast tissue samples were also included as controls. qRT-PCR was used for validation. All DCIS and invasive samples could be classified into the "intrinsic" molecular subtypes defined for invasive breast cancer. Hierarchical clustering establishes that samples group by intrinsic subtype, and not by diagnosis. We observed heterogeneity in the transcriptomes among DCIS of high histological grade and identified a distinct subgroup containing seven of the 31 DCIS samples with gene expression characteristics more similar to advanced tumours. A set of genes independent of grade, ER-status and HER2-status was identified by logistic regression that univariately classified a sample as belonging to this distinct DCIS subgroup. qRT-PCR of single markers clearly separated this DCIS subgroup from the other DCIS, and contains samples from several histopathological and intrinsic molecular subtypes. The genes that differentiate between these two types of DCIS suggest several processes related to the re-organisation of the microenvironment. This raises interesting possibilities for identification of DCIS lesions both with and without invasive characteristics, which potentially could be used in clinical assessment of a woman's risk of progression, and lead to improved management that would avoid the current over- and under-treatment of patients. (c) 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20663721      PMCID: PMC5527914          DOI: 10.1016/j.molonc.2010.06.007

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  52 in total

1.  Expression profiling of epithelial plasticity in tumor progression.

Authors:  Martin Jechlinger; Stefan Grunert; Ido H Tamir; Elzbieta Janda; Susanna Lüdemann; Thomas Waerner; Peter Seither; Andreas Weith; Hartmut Beug; Norbert Kraut
Journal:  Oncogene       Date:  2003-10-16       Impact factor: 9.867

Review 2.  Treatment of DCIS--results from clinical trials.

Authors:  Jack Cuzick
Journal:  Surg Oncol       Date:  2003-12       Impact factor: 3.279

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression?

Authors:  Eva A Turley; Mandana Veiseh; Derek C Radisky; Mina J Bissell
Journal:  Nat Clin Pract Oncol       Date:  2008-03-18

5.  Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer.

Authors:  Bjørn Naume; Xi Zhao; Marit Synnestvedt; Elin Borgen; Hege Giercksky Russnes; Ole Christian Lingjaerde; Maria Strømberg; Gro Wiedswang; Gunnar Kvalheim; Rolf Kåresen; Jahn M Nesland; Anne-Lise Børresen-Dale; Therese Sørlie
Journal:  Mol Oncol       Date:  2007-04-04       Impact factor: 6.603

6.  Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures.

Authors:  M D Lagios; P R Westdahl; F R Margolin; M R Rose
Journal:  Cancer       Date:  1982-10-01       Impact factor: 6.860

7.  Supervised risk predictor of breast cancer based on intrinsic subtypes.

Authors:  Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

8.  Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer.

Authors:  Theresa Casey; Jeffrey Bond; Scott Tighe; Timothy Hunter; Laura Lintault; Osman Patel; Jonathan Eneman; Abigail Crocker; Jeffrey White; Joseph Tessitore; Mary Stanley; Seth Harlow; Donald Weaver; Hyman Muss; Karen Plaut
Journal:  Breast Cancer Res Treat       Date:  2008-03-29       Impact factor: 4.872

9.  Molecular markers in ductal carcinoma in situ of the breast.

Authors:  Dale Porter; Jaana Lahti-Domenici; Aparna Keshaviah; Young Kyung Bae; Pedram Argani; Jeffrey Marks; Andrea Richardson; Amiel Cooper; Robert Strausberg; Gregory J Riggins; Stuart Schnitt; Edward Gabrielson; Rebecca Gelman; Kornelia Polyak
Journal:  Mol Cancer Res       Date:  2003-03       Impact factor: 5.852

10.  Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds.

Authors:  Howard Y Chang; Julie B Sneddon; Ash A Alizadeh; Ruchira Sood; Rob B West; Kelli Montgomery; Jen-Tsan Chi; Matt van de Rijn; David Botstein; Patrick O Brown
Journal:  PLoS Biol       Date:  2004-01-13       Impact factor: 8.029

View more
  56 in total

1.  Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.

Authors:  José M A Moreira; Teresa Cabezón; Irina Gromova; Pavel Gromov; Vera Timmermans-Wielenga; Isidro Machado; Antonio Llombart-Bosch; Niels Kroman; Fritz Rank; Julio E Celis
Journal:  Mol Oncol       Date:  2010-10-08       Impact factor: 6.603

2.  Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions.

Authors:  Helga Bergholtz; Tonje G Lien; David M Swanson; Arnoldo Frigessi; Maria Grazia Daidone; Jörg Tost; Fredrik Wärnberg; Therese Sørlie
Journal:  NPJ Breast Cancer       Date:  2020-06-17

3.  Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis.

Authors:  Thomas Fleischer; Arnoldo Frigessi; Kevin C Johnson; Hege Edvardsen; Nizar Touleimat; Jovana Klajic; Margit Lh Riis; Vilde D Haakensen; Fredrik Wärnberg; Bjørn Naume; Aslaug Helland; Anne-Lise Børresen-Dale; Jörg Tost; Brock C Christensen; Vessela N Kristensen
Journal:  Genome Biol       Date:  2014-08-22       Impact factor: 13.583

Review 4.  Ductal carcinoma in situ of breast: update 2019.

Authors:  Sunil S Badve; Yesim Gökmen-Polar
Journal:  Pathology       Date:  2019-08-28       Impact factor: 5.306

5.  p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer.

Authors:  C Lodillinsky; E Infante; A Guichard; R Chaligné; L Fuhrmann; J Cyrta; M Irondelle; E Lagoutte; S Vacher; H Bonsang-Kitzis; M Glukhova; F Reyal; I Bièche; A Vincent-Salomon; P Chavrier
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

Review 6.  Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ.

Authors:  Bethany N Hannafon; Wei-Qun Ding
Journal:  Am J Pathol       Date:  2018-09-29       Impact factor: 4.307

7.  Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.

Authors:  Pradeep Chaluvally-Raghavan; Fan Zhang; Sunila Pradeep; Mark P Hamilton; Xi Zhao; Rajesha Rupaimoole; Tyler Moss; Yiling Lu; Shuangxing Yu; Chad V Pecot; Miriam R Aure; Sylvain Peuget; Cristian Rodriguez-Aguayo; Hee-Dong Han; Dong Zhang; Avinashnarayan Venkatanarayan; Marit Krohn; Vessela N Kristensen; Mihai Gagea; Prahlad Ram; Wenbin Liu; Gabriel Lopez-Berestein; Philip L Lorenzi; Anne-Lise Børresen-Dale; Koei Chin; Joe Gray; Nelson J Dusetti; Sean E McGuire; Elsa R Flores; Anil K Sood; Gordon B Mills
Journal:  Cancer Cell       Date:  2014-12-08       Impact factor: 31.743

8.  Molecular Markers as Prognostic Factors in DCIS and Small Invasive Breast Cancers.

Authors:  N Sänger; K Engels; A Graf; E Ruckhäberle; K E Effenberger; T Fehm; U Holtrich; S Becker; T Karn
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-11       Impact factor: 2.915

Review 9.  Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ.

Authors:  Hitchintan Kaur; Shihong Mao; Seema Shah; David H Gorski; Stephen A Krawetz; Bonnie F Sloane; Raymond R Mattingly
Journal:  Expert Rev Mol Diagn       Date:  2013-03       Impact factor: 5.225

10.  Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines.

Authors:  Natascia Marino; Joshua W Collins; Changyu Shen; Natasha J Caplen; Anand S Merchant; Yesim Gökmen-Polar; Chirayu P Goswami; Takashi Hoshino; Yongzhen Qian; George W Sledge; Patricia S Steeg
Journal:  Clin Exp Metastasis       Date:  2014-08-03       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.